Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug

NEW YORK – Roche subsidiary Foundation Medicine announced on Thursday that it is partnering with Boehringer Ingelheim to develop a companion diagnostic for the pharmaceutical firm's biliary tract cancer drug.

The companies will develop the tissue-based FoundationOne CDx test as a companion diagnostic for BI 907828 in the US, Japan, and the EU, Foundation said in a statement. The drug is an investigational, oral, small molecule MDM2-p53 antagonist. It is being evaluated as monotherapy in Brightline-2, an ongoing Phase IIa/IIb multicenter trial for the treatment of patients with locally advanced or metastatic, MDM2 amplified, TP53 wild-type biliary tract cancer who have progressed on standard of care therapy.

FoundationOne CDx is a next-generation sequencing-based test that detects substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements. It also detects genomic signatures like microsatellite instability and tumor mutational burden.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.